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Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies
targeting HDL have failed to show beneﬁts vs. placebo.
Objective ToinvestigatetheeffectsofanHDL-mimeticagentonatherosclerosisbyintravascularultrasonography(IVUS)andquan-
titative coronary angiography (QCA).
Design and
setting
Aprospective,double-blinded,randomizedtrialwasconductedat51centresintheUSA,theNetherlands,Canada,and
France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and
3 (2–5) weeks after the last study infusion.
Patients Fivehundredandsevenpatientswererandomized;417and461hadpairedIVUSandQCAmeasurements,respectively.
Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001.
Main outcome
measures
Theprimaryefﬁcacyparameterwasthenominalchangeinthetotalatheromavolume.Nominalchangesinpercentath-
eroma volume on IVUS and coronary scores on QCA were also pre-speciﬁed endpoints.
Results The nominal change in the total atheroma volume (adjusted means) was 22.71, 23.13, 21.50, and 23.05 mm
3 with
placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P ¼ 0.81).
There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, 20.02, 0.01,
and 0.19%; nominal P ¼ 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was 20.022, 20.036,
20.022, and 20.015 mm (nominal P ¼ 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score
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was 20.51, 2.65, 0.71, and 20.77% (compared with placebo, nominal P ¼ 0.85 for 12 mg/kg and nominal P ¼ 0.01 for
3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and
12 (9.8%) in the four groups.
Conclusion CER-001infusionsdidnotreducecoronaryatherosclerosisonIVUSandQCAwhencomparedwithplacebo.Whether
CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await
further study.
Name of the trial registry: Clinicaltrials.gov; Registry’s URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=
cer-001&rank=2; Trial registration number: NCT01201837.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Translational perspective
Although there is extensive epidemiological and pre-clinical evidence supporting favourable cardiovascular effects of HDL, clinical trials of
HDL-basedtherapieshaveoftenyieldeddisappointingresults.Here,wereporttheresultsoftheCHI-SQUAREstudy,thelargestrandomized
clinicaltrialperformedsofarofserialHDLinfusionsinpatientswitharecentacutecoronarysyndrome.Inthisstudy,theHDL-mimeticagent
CER-001didnotreducecoronaryatherosclerosisonIVUSandQCAwhencomparedwithplacebo.WhetherCER-001administeredinother
regimens or to other populations could favourably affect atherosclerosis is not known.
Introduction
Patients with a recent acute coronary syndrome are exposed to
a high risk of recurrent events during the ﬁrst year after the initial
presentation despite intensive contemporary treatment.
1 Athero-
sclerosisisthemainunderlyingaetiologyfortheimportantcardiovas-
cular disease burden in our societies.
2 Therefore, further strategies
todecreaseatherosclerosisburdenandimprovecardiovascularout-
comes are needed. There is an inverse association between high-
density lipoprotein (HDL) cholesterol and risk of coronary heart
disease complications in population-based epidemiological studies,
3
although HDL particle number appears to be a better predictor of
outcomes in the current era of aggressive statin use and very low
LDL cholesterol levels.
4 Yet recent data have indicated that this
inverse relationship is substantially weakened in patients with mani-
festcoronaryheartdisease.
5Severaltrialshavereporteddisappoint-
ing results with medications affecting HDL such as niacin and
cholesteryl ester transfer protein inhibitors, although some of
thesestudiesmayhavecontainedconfoundingfactors.
6–9Threeclin-
ical studies have suggested beneﬁts of HDL infusions on coronary
plaque burden evaluated by intravascular ultrasonography (IVUS)
when compared with baseline, but none established signiﬁcance vs.
placebo.
10–12 Interpretation of the latter studies was limited by the
small sample sizes
10–12 and imbalances among groups in plaque
burden at baseline.
10
CER-001 is an engineered lipoprotein particle mimicking
pre-beta HDL and consisting of a combination of recombinant
human apolipoprotein A-I and two phospholipids. It has previously
been shown to rapidly mobilize large amounts of cholesterol into
the HDL fraction following its i.v. administration.
13 The objective
of the current study was to assess the safety and efﬁcacy of
CER-001 administered as a series of weekly infusions on coronary
atherosclerosisasassessedbyIVUSandquantitativecoronaryangi-
ography (QCA).
Methods
Study design and population
BetweenMarch2011 andAugust2012,patients withaclinical indication
for coronary angiography and a research-mandated IVUS recording
approved by the IVUS core laboratory were randomized to receive
either placebo or CER-001 infusions within 14 days of having an acute
coronary syndrome deﬁned as unstable angina, non-ST or ST segment
elevation myocardial infarction. Eligible patients were women (without
childbearing potential) and men up to 80 years of age with at least one
narrowing of 20% or more on coronary angiography at baseline or
historyofpercutaneouscoronaryintervention (PCI)(theinfarct-related
arteryand all coronaryarteries undergoing PCI were excludedfromthe
imaging analysis). Patients with .50% stenosis in the left main coronary
artery, a baseline IVUS recording determined to be of unacceptable
qualitybytheIVUScorelaboratory,renalinsufﬁciency(serumcreatinine
.2.0 mg/dL),liverdisease(enzymesgreaterthantwicetheupperlimitof
normal), uncontrolled diabetes mellitus (HbA1C .10%), triglycerides
.500 mg/dL, uncontrolled hypertension, haemodynamic instability,
class III or IV heart failure, known ejection fraction ,35%, previous or
planned coronary bypass surgery, valvular disease requiring cardiac
surgery, or history of alcohol or drug abuse were excluded from study
participation. Institutional ethics committees approved the protocol at
all 51 participating study centres in the USA, the Netherlands, Canada,
and France, and all trial patients provided written informed consent
before any study procedure was performed.
The CHI-SQUARE study was a randomized, double-blinded, placebo-
controlled, ascending dose trial. Qualifying patients were randomly
assigned to receive six weekly volume-matched infusions of either
CER-001 or placebo in a 3:1 ratio in three consecutive cohorts
(CER-001 3 mg/kg vs. placebo, then 6 mg/kg vs. placebo, and ﬁnally
12 mg/kgvs.placebo),resultinginsimilarnumbersofpatientsrandomized
to the four study arms (placebo, CER-001 3, CER-001 6, and CER-001
12 mg/kg).Therandomizationcodeusedblocksofsize4andwasstratiﬁed
according to site and cohort, and was generated by the Montreal Heart
Institute Coordinating Center using the SAS procedure PROCPLAN and
J.-C. Tardif et al. 3278managedcentrallyviaaninteractiveresponsesystemtoensureanascend-
ing dose study design.
Priortorandomization,abaselineIVUSexaminationofthedesignated
target coronary artery was performed and transferred to the Montreal
HeartInstitutecoreIVUSlaboratoryforaqualityassessment.Theprox-
imal 4 cm of the target coronaryartery in which IVUS was performed at
baselineneededtohaveareferencediameterof2.5 mmormore,befree
ofﬁllingdefectssuggestiveofthrombosis,nottohave .50%reductionin
lumen diameter by visual angiographic estimation at baseline, and not to
have undergone previous PCI nor be a candidate for intervention at the
time of the baseline catheterization or over the following 12 weeks.
Threeweeksafterthelaststudyinfusion(2–5weekwindow),afollow-up
IVUS examination was performed in the same segment of the target
artery studied at baseline.
A follow-up visit occurred  6 months after the last dose of study
medication to monitor for major adverse cardiovascular events and
anti-apoA-I antibodies. Patient safety was monitored throughout the
trial. Clinical blood laboratory data were evaluated on an ongoing basis
throughout the study. An independent, unblinded safety monitoring
committee met at intervals during the trial (including near the end of
the recruitment of the ﬁrst two cohorts to authorize dose escalation).
Intervention and blinding
CER-001 (Cerenis, France) is a negatively charged lipoprotein complex
mimicking discoidal pre-beta HDL, consisting of recombinant human
apolipoprotein A-I and a combination of two naturally occurring
phospholipids. The apolipoprotein A-I component is expressed in
mammalian CHO cells and puriﬁed by a three-step column chromatog-
raphy process. The phospholipid component consists of egg sphingo-
myelin and 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol)
(dipalmitoylphosphatidyl-glycerol) in a 97 : 3 weight ratio. The ratio
of protein to total phospholipids in the CER-001 complex is 1 :2.7
weight/weight.ThedrugproductisasolutionoftheCER-001complexes
in phosphate buffered sucrose/mannitol solution (10 mM phosphate
buffer, 4.0% sucrose, 2.0% mannitol, pH 8.0). The concentration of
CER-001complexesintheformulationisexpressedastheconcentration
ofthe apolipoproteinA-I component. Intravenous infusions of CER-001
or placebo (saline with all non-active ingredients of CER-001) were
administered over 1 h.
The site pharmacist or designee dispensing study drug was unblinded
to individual patient treatment allocation but had no other role in study
conduct. All other site personnel, the patients, blinded study monitor,
studymanagementteam,andsponsor,wereblindedtotreatmentalloca-
tion.Studydrugblindingwasachievedbyshroudingthei.v.containerwith
anopaquebag,sealedbythepharmacist.Boththeplacebosalinesolution
and CER-001 solutions remained shrouded until the infusions were
administered and returned to the pharmacy.
Intravascular ultrasonography and coronary
angiography
The methods for IVUS image acquisition and measurement in athero-
sclerosis studies have been described previously.
11,14–18 Intravascular
ultrasonographyexaminationswereperformedusing40–45 MHzcathe-
tersatbaselineandfollow-up.ThesametypeofIVUScatheter(Volcano
CorporBostonScientiﬁc)wasusedandthesamedoseofintracoronary
nitroglycerine (0.15 mg) was administered prior to automated IVUS
pullbacks performed at both time-points. All IVUS examinations were
analysedattheMontrealHeartInstitutecorelaboratorybyexperienced
technicianssupervisedbyacardiologistblindedtotreatmentassignment,
according to published standards.
19 The lumen and external elastic
membraneborders were manually traced on 31 digitized cross-sections
matchedatbaselineandfollow-up(fewerifitwasnotpossibletooptimal-
lymatch31cross-sections,butatleast16matchedframesweretracedat
both time-points in all cases) and selected throughout the segment of
interest.Thetotalatheromavolumewascomputedthroughthesumma-
tion ofplaque areas(the latterisequal tothe external elasticmembrane
area minus the lumen area) of all traced cross-sections for the segment,
and results were then indexed to a 30-mm segment to compensate
for differences in segment length between subjects and to allow each
patient to contribute equally to the overall result (indexation to a
30-mm segment was performed by dividing atheroma volume by the
length of the reconstructed segment and multiplying by 30). Per cent
atheromavolumewascomputedbydividing atheromavolumebyexter-
nal elastic membrane volume and then multiplying by 100%.
Carewastakentoensureidenticalconditionsduringtheangiographic
examinations at baseline and follow-up (catheters, contrast media, and
projections). Intracoronary nitroglycerine (0.15 mg) was administered
into each coronary artery before angiographic injection. The segments
of interest were visualized in multiple transverse and sagittal views to
clearly separate stenosis from branches, minimize foreshortening, and
obtainviewsasperpendicularaspossibletothelongaxisofthesegments
to be analysed. All angiograms were analysed at the MHI QCA core
laboratory using the CMS system (MEDIS, Leiden, Netherlands).
20,21
Quantitativecoronaryangiographywasperformedbyexperiencedtech-
nicians supervised by an expert physician in matched projections from
baseline and follow-up angiograms.
17 For each lesion, an end-diastolic
frame from both angiograms was selected with identical angulations
that best showed the stenosis at its most severe degree with minimal
foreshortening and branch overlap. All intervened coronary arteries
wereexcludedfromtheanalysis.Thecoronaryarterysegmentsanalysed
included all those with a reference diameter ≥1.5 mm and a stenosis
≥20% at baseline, and those with new lesions at follow-up. Computer
software automatically calculated the minimum lumen diameter
(MLD), reference diameter, and per cent diameter stenosis.
Efﬁcacy parameters
The primary efﬁcacy endpoint was the nominal change in the total
atheroma volume (follow-up minus baseline) on IVUS. Secondary and
exploratory efﬁcacy measures included, respectively, the nominal
change in per cent atheroma volume on IVUS, and the nominal changes
in the coronary artery score (deﬁned as the per-patient mean of MLD
for all lesions measured) and in the cumulative coronary stenosis score
(calculated as the summation of the per cent diameter stenosis of all
lesions measured) on QCA. The cumulative coronary stenosis score is
anindexoftheanatomicextensionandseverityofdiseaseinallcoronary
arteries.
22
Safety and clinical event evaluations
Patient safety was assessed by monitoring adverse events, physical
examinations, electrocardiograms, and clinical laboratory results. All
blood-related analyses were carried out centrally. A clinical endpoint
committee adjudicated all major adverse cardiovascular events having
occurred between the ﬁrst administration of study drug and 6 months
after the last administration of study drug, including death, resuscitated
cardiacarrest,non-fatalmyocardialinfarction,non-fatalstroke,coronary
revascularization procedures (PCI and coronary bypass graft surgery),
hospitalization for unstable angina and hospitalization for heart failure,
according to established deﬁnitions.
Statistical analysis
The primary analysis was based on the modiﬁed intent-to-treat popula-
tion, which included all randomized subjects with a post-randomization
Effects of CER-001 on atherosclerosis 3279efﬁcacyrecording,irrespectiveoftheirprotocoladherence.Asensitivity
analysis was performed on the per-protocol population, which included
subjects who were part of the modiﬁed intent-to-treat population and
received all six infusions of study drug at the planned dosage without
major protocol deviations. Safety results are presented for all patients
who received at least one study infusion.
Parametric analyses were performed after basic assumptions were
checked. The primary endpoint (nominal change in the total atheroma
volume) was analysed using an analysis of a covariance model that
included the treatment group and baseline value as a covariate. The
adjusted mean in the CER-001 12 mg/kg group was compared with the
adjusted mean in the placebo group at the 0.05 signiﬁcance level and
this comparison was considered as the primary analysis. Under the
same analysis of the covariance model, the adjusted means in the other
CER-001 groups (6 and 3 mg/kg) were compared with the adjusted
mean in the placebo group; the change from baseline within each treat-
ment group was also tested. These analyses of the primary endpoint
were considered exploratory. Other IVUS and QCA endpoints
expressedasanominalchangefrombaselinetofollow-upwereanalysed
asdescribedaboveusingananalysisofthecovariancemodeladjustingfor
the baseline value of the parameter.
Sample size computation was based on an expected difference of at
least 7 mm
3 in change in the total atheroma volume between the
CER-001 12 mg/kg and placebo groups. Assuming that the standard de-
viation of the change in the total atheroma volume would be 15 mm
3
in both groups and using a two-sided 0.05 signiﬁcance level, 98 subjects
per treatment group were necessary to detect this difference with 90%
power. To account for an attrition rate of 20–25%, 126 subjects per
group were to be randomized for a total of 504 patients. Statistical
analyses were performed using SAS version 9.3.
Results
Baseline demographics
Five hundred and seven patients were randomized (Figure 1) and
baseline patient characteristics were similar among groups
(Table 1). There were 417 and 461 patients with paired IVUS and
QCA measurements, respectively. The main reasons for the lack of
IVUS analysis were early study termination and inability to obtain a
matched coronary segment at both time points (Figure 1). The per-
centagesofpatientswhoreceivedallsixplannedstudydruginfusions
in the primary analysis (modiﬁed intent-to-treat) population were
97.5, 100, 96.7, and 91.4% in the placebo, CER-001 3, 6, and 12 mg/kg
groups (P ¼ 0.004).
Imaging efﬁcacy results
Intravascularultrasonographyimagesweretracedoverameanarter-
ial segment length of 48+15 mm (Table 2). The mean total ather-
oma volume at baseline was 155.24+67.99 mm
3. The adjusted
means for change in the total atheroma volume were 22.71,
23.13, 21.50, and 23.05 mm
3 in the placebo, CER-001 3, 6, and
12 mg/kg groups (P ¼ 0.81 for the pre-speciﬁed primary analysis of
12 mg/kg vs. placebo). There were also no differences compared
with placebo for the CER-001 6 mg/kg (nominal P ¼ 0.45) and
3 mg/kg(nominalP ¼ 0.77)groups.Thechangeinpercentatheroma
volume was similar among all study groups [0.02, 20.02, 0.01, and
0.19% in the placebo, CER-001 3 mg/kg (P ¼ 0.86), 6 mg/kg (P ¼
0.95), and 12 mg/kg (P ¼ 0.53) groups (nominal P-values vs.
placebo)].Asensitivityanalysisconductedontheper-protocolpopu-
lation,whichhad 97% power todetectthetarget difference giventhe
observed standard deviation, yielded similar results (Table 2).
QuantitativecoronaryangiographyresultsaredescribedinTable4.
The change from baseline to follow-up in the coronary artery score
was 20.022, 20.036, 20.022, and 20.015 mm in the placebo and
CER-001 3, 6, and 12 mg/kg groups, respectively (vs. placebo,
nominalP ¼ 0.25,0.99,0.55,respectively).Thechangefrombaseline
to follow-up in the cumulative coronary stenosis score was 20.51,
2.65, 0.71, and 20.77% in the placebo and CER-001 3, 6, and
12 mg/kg groups (nominal P ¼ 0.01 for 3 mg/kg vs. placebo).
Cardiovascular events
Thenumberofpatientswithatleastonemajoradversecardiovascu-
lar event was 10 (8.3%) in the placebo group, and 16 (13.3%), 17
(13.7%), and 12 (9.8%) in the CER-001 groups, without statistically
signiﬁcant differences (Table 5).
Safety results
CER-001wasgenerallywelltoleratedduringthestudy(Table6).There
were a few infusion-type reactions during the study, which led to the
temporary halting of patient recruitment (without interrupting
ongoing study drug administration) to allow updating ofthe informed
consentdocumentaspertherecommendationofthesafetymonitor-
ingcommitteefollowingitsperiodicreviewwhichincludedallsubjects
from the ﬁrst two study cohorts and 128 subjects from the third
cohort. Drug-related hypersensitivity reported as a serious adverse
event occurred in 0, 1, 3, and 2 patients in the placebo and CER-001
groups. Treatment-emergent infusion-type reactions (with rigors,
chills, nausea, and/or hypotension) occurred in 0, 0, 3, and 3 patients
of the placebo, CER-001 3, 6, and 12 mg/kg groups, respectively.
None of these patients had anti-apoA-I antibodies.
Treatment-emergentelevationsinALT(threetimestheULN)oc-
curred in 2, 2, 2, and 1 patients in the four study groups.
Post hoc re-analysis
Attheendofthestudy,thesponsorrequestedaposthocre-analysisof
theIVUSrecordingsbyaseparategroup,whichalsoshowedthatthe
primary endpoint was not met (Table 3). The adjusted means for
change in the total atheroma volume were 22.85, 24.76, 23.34,
and 22.61 mm
3 in the placebo, CER-001 3 mg/kg (P ¼ 0.28), 6 mg/kg
(P ¼ 0.78), and 12 mg/kg (P ¼ 0.89) groups (nominal P-values vs.
placebo). A sensitivity analysis performed on the per-protocol
population of these post hoc re-analysed data yielded similar results
(Table 3).
Discussion
This study did not demonstrate positive effects of the HDL-mimetic
agent CER-001 on coronary atherosclerosis evaluated by IVUS and
QCA. In the main modiﬁed intent-to-treat population, the differences
in adjusted means of change in the total atheroma volume (active arm
minusplacebo)were20.34 mm
3forCER-00112 mg/kg(primaryend-
point,P ¼ 0.81),1.20 mm
3for6 mg/kg,and20.42 mm
3for3 mg/kg.In
the per-protocol population, corresponding changes vs. placebowere
20.51, 0.90, and 22.00 mm
3 for the CER-001 12, 6, and 3 mg/kg
groups, respectively. The difference of 22m m
3 between the
J.-C. Tardif et al. 3280Figure 1 Disposition of patients in the trial.
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wassmallandnotnominallysigniﬁcant(nominalP ¼ 0.22).Theposthoc
re-analysisofIVUSrecordingsrequestedbythesponsoryieldedresults
similar to those of the pre-speciﬁed primary analysis.
This result on IVUS was accompanied by an increase of 3.15% of
the cumulative coronary stenosis score on QCA in the CER-001
3 mg/kg group compared with placebo (nominal P ¼ 0.01), which
suggeststhattherewasprogressivelygreaterobstructionofcoronary
...............................................................................................................................................................................
Table 1 Characteristics of patients in the modiﬁed intent-to-treat population (n 5 470)
Randomization group Placebo
(n 5 118)
CER-001, 3 mg/kg
(n 5 116)
CER-001, 6 mg/kg
(n 5 120)
CER-001, 12 mg/kg
(n 5 116)
Age (years), means+SD 59.0+9.0 57.3+9.3 59.1+9.3 60.5+9.6
Men, n (%) 86 (72.9) 93 (80.2) 90 (75.0) 85 (73.3)
Weight (kg), means+SD 90.2+15.3 89.2+17.8 89.8+17.3 89.5+19.5
Current smoking, n (%) 30 (25.4) 34 (29.3) 31 (25.8) 31 (26.7)
Hypertension, n (%) 89 (75.4) 82 (70.7) 82 (68.3) 71 (61.2)
Diabetes, n (%) 36 (30.5) 27 (23.3) 29 (24.2) 25 (21.6)
Prior MI, n (%) 26 (22.0) 19 (16.4) 16 (13.3) 12 (10.3)
Prior PCI, n (%) 42 (35.6) 30 (25.9) 31 (25.8) 19 (16.4)
Lipid-lowering agent use, n (%) 114 (96.7) 114 (98.3) 116 (96.8) 113 (97.4)
Apo-B (mg/dL), Mean+SD 79.9+21.5 78.7+22.8 85.7+25.8 81.1+23.4
Apo A-I (mg/dL), Mean+SD 130.2+21.7 129.7+22.2 131.1+22.9 134.7+22.9
Presentation, n (%)
Unstable angina 65 (55.1) 68 (58.6) 53 (44.2) 60 (51.7)
NSTEMI 41 (34.7) 37 (31.9) 59 (49.2) 50 (43.1)
STEMI 12 (10.2) 11 (9.5) 8 (6.7) 6 (5.2)
Apo, apolipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention.
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 2 Primary intravascular ultrasonography results
Modiﬁed intent-to-treat population,
total atheroma volume (mm
3)
Placebo
(n 5 101)
CER-001, 3 mg/kg
(n 5 105)
CER-001, 6 mg/kg
(n 5 106)
CER-001, 12 mg/kg
(n 5 105)
Baseline (means+SD) 160.57+59.99 141.01+60.91 162.13+78.86 157.37+68.98
Follow-up (means+SD) 157.70+59.08 138.32+59.43 160.41+77.81 154.26+67.43
Nominal change (adjusted mean) (95% CI) 22.71 (24.89, 20.53) 23.13(25.03, 21.24) 21.50(23.76,0.75) 23.05(24.79, 21.30)
P-value vs. placebo N/A 0.77 0.45 0.81*
Per cent atheroma volume (%)
Baseline (mean+SD) 38.03+8.97 34.63+9.13 37.37+9.32 36.86+9.09
Follow-up (mean+SD) 38.01+8.90 34.69+8.91 37.35+8.97 37.04+9.22
Nominal change (adjusted mean) (95% CI) 0.02 (20.31, 0.35) 20.02 (20.35, 0.31) 0.01 (20.31, 0.33) 0.19 (20.22, 0.60)
P-value vs. placebo N/A 0.86 0.95 0.53
Per-protocol population, total atheroma volume (mm
3)( n ¼ 82) (n ¼ 78) (n ¼ 80) (n ¼ 78)
Baseline (means+SD) 158.65+58.98 141.66+64.10 160.79+77.61 153.86+65.93
Follow-up (means+SD) 156.17+58.39 137.67+61.93 159.14+76.49 151.01+65.34
Nominal change (adjusted mean) (95% CI) 22.34 (24.71, 0.03) 24.34(26.48, 22.19) 21.45(24.17,1.27) 22.85(24.85, 20.85)
P-value vs. placebo N/A 0.22 0.62 0.74
Per cent atheroma volume (%)
Baseline (mean+SD) 37.59+9.01 34.10+8.71 37.37+9.63 36.93+9.00
Follow-up (mean+SD) 37.58+9.00 34.12+8.58 37.30+9.25 37.02+9.27
Nominal change (adjusted mean) (95% CI) 0.02 (20.34, 0.38) 20.05 (20.45, 0.34) 20.05(20.42,0.33) 0.10 (20.41, 0.61)
P-value vs. placebo N/A 0.78 0.80 0.80
*P-value for primary endpoint (in bold). All other P-values represent nominal values.
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22Thedifferenceamonggroupsforthe
changeinthecoronaryarteryscore,however,didnotreachstatistical
signiﬁcance.
Intheexploratoryanalysisofmajoradversecardiovascularevents,
there was no statistically signiﬁcant difference in the time to ﬁrst
event analysis or in the individual clinical endpoints, although this
study was not powered for these outcomes.
Although CHI-SQUARE is much larger than the previous three
clinical studies of HDL infusions,
9–11 none of these trials has been
able to demonstrate a therapeutic beneﬁt on coronary atheroscler-
osis evaluated by IVUS compared with placebo using the
intention-to-treat principle. Given that all four studies have focused
on patients with a recent acute coronary syndrome, it is not
known if CER-001 could be effective in other patient populations.
...............................................................................................................................................................................
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Table 4 Quantitative coronary angiography results
Modiﬁed intent-to-treat population,
coronary artery score (mm)
Placebo
(n 5 116)
CER-001, 3 mg/kg
(n 5 115)
CER-001, 6 mg/kg
(n 5 119)
CER-001, 12 mg/kg
(n 5 111)
Baseline (means+SD) 1.961+0.385 2.034+0.392 2.003+0.438 1.985+0.499
Follow-up (means+SD) 1.940+0.384 1.997+0.382 1.981+0.436 1.970+0.502
Nominal change(adjusted mean) (95% CI) 20.022 (20.039, 20.006) 20.036(20.052, 20.020) 20.022(20.038, 20.006) 20.015(20.032,0.001)
P-value vs. placebo N/A 0.25 0.99 0.55
Cumulative coronary stenosis score (%)
Baseline (means+SD) 167.66+100.73 169.27+105.90 181.23+109.01 165.81+111.18
Follow-up (means+SD) 167.13+101.04 171.90+108.72 182.00+109.41 165.01+111.20
Nominal change (adjusted mean)
(95% CI)
20.51 (22.42, 1.41) 2.65 (1.00, 4.29) 0.71 (21.40, 2.82) 20.77 (22.66, 1.13)
P-value vs. placebo N/A 0.01 0.40 0.85
Given that the P-value for the primary endpoint was not signiﬁcant, all P-values in this table represent nominal values.
...............................................................................................................................................................................
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Table 3 Post hoc reanalysis of intravascular ultrasonography data
Modiﬁed intent-to-treat population,
total atheroma volume (mm
3)
Placebo
(n 5 93)
CER-001, 3 mg/kg
(n 5 88)
CER-001, 6 mg/kg
(n 5 100)
CER-001, 12 mg/kg
(n 5 88)
Baseline (means+SD) 148.34+57.06 133.54+51.97 149.16+72.19 146.21+60.81
Follow-up (means+SD) 145.32+55.58 129.23+50.92 145.63+70.97 143.52+59.09
Nominal change (adjusted mean) (95% CI) 22.85(25.27,20.43) 24.76 (27.25, 22.26) 23.34(25.67,21.00) 22.61(25.10,20.13)
P-value vs. placebo N/A 0.28 0.78 0.89
Per cent atheroma volume (%)
Baseline (means+SD) 36.35+9.11 34.54+8.11 36.67+9.09 35.87+8.70
Follow-up (means+SD) 36.16+9.12 34.04+7.81 36.23+8.87 36.09+8.95
Nominal change (adjusted mean) (95% CI) 20.17 (20.66, 0.33) 20.56 (21.07, 20.05) 20.41 (20.89, 0.06) 0.22 (20.28, 0.73)
P-value vs. placebo N/A 0.27 0.48 0.28
Per-protocol population,total atheromavolume (mm
3)( n ¼ 67) (n ¼ 66) (n ¼ 72) (n ¼ 65)
Baseline (mean+SD) 150.35+56.90 134.97+53.82 146.44+72.47 144.93+61.52
Follow-up (mean+SD) 146.41+54.84 129.16+52.13 143.50+69.58 143.08+60.07
Nominal change (adjusted mean) (95% CI) 23.63(26.34,20.91) 26.28 (29.02, 23.54) 22.83(25.44,20.21) 21.81 (24.56, 0.95)
P-value vs. placebo N/A 0.18
a 0.68 0.36
Per cent atheroma volume (%)
Baseline (mean+SD) 36.91+8.88 34.10+7.44 36.92+9.42 36.10+8.41
Follow-up (mean+SD) 36.59+8.90 33.45+7.21 36.40+9.13 36.47+8.78
Nominal change (adjusted mean) (95% CI) 20.28 (20.87, 0.31) 20.74 (21.33, 20.14) 20.48 (21.04, 0.09) 0.37 (20.22, 0.97)
P-value vs. placebo N/A 0.28 0.63 0.13
aIn a non-parametric test not performed by the academic statistical centre, the nominal P was 0.03.
Effects of CER-001 on atherosclerosis 3283Whetherotherdosingregimens(e.g.highernumberofinfusions,dif-
ferent dosage) could lead to a more favourable outcome is also
unknown. It is also possible that the different lipoprotein composi-
tionsofthesefourHDL-relatedcomplexesmayaffecttheireffective-
ness. The fact that the dose-related increase in cholesterol
mobilization in the current study (estimated by the increase in
plasma cholesterol after CER-001 infusion, see Supplementary
Data) did not translate into progressively greater effects on IVUS
underscores the lack of predictive value of this biomarker. Other
properties of HDL particles, like their anti-inﬂammatory effects
23
or changes in their proteome,
24 could be of greater importance.
Nevertheless, the plasma level of free cholesterol increased by
 45% at 2 h after the start of the infusion of CER-001 12 mg/kg.
The signiﬁcance of this result obtained ata single time point after in-
fusion is not entirely clear. Interestingly, in a previous phase I clinical
study, signiﬁcant increases in the plasma level of cholesteryl esters
were observed after the infusion of CER-001 at dosages of 15 and
45 mg/kg.
13Inthatstudy,noclinicallysigniﬁcantchangesinlaboratory
red blood cell parameters were observed in humans with CER-001
doses up to 45 mg/kg. Similarly, no changes in red blood cell
morphologic parameters were observed in in vitro compatibility
studiesusinghumanredbloodcellsandCER-001ata30-foldconcen-
tration margin over the highest dose used in the current study. Al-
though its source is not entirely certain, the majority of the
cholesterol mobilized into circulation likely comes from the liver,
as previously proposed.
25
There were six patients treated with CER-001 who experienced
non-fatal infusion reactions (3 with 6 mg/kg and 3 with 12 mg/kg).
Thepathophysiologyofthesereactionsisuncertain,butnotassociated
with anti-apoA-I antibodies or obvious complement depletion. An
infusion reaction was also reported in the apoA-I Milano study.
9
One study limitation was that it was not powered to detect
differences in clinical outcomes among groups. Also, there was no
assessmentofpotentialchangesinplaquequalitybyvirtualhistology,
whichmayhaveconcealedpotentiallyfavourableeffectsofthisthera-
peuticapproachinthelongterm.Increasingemphasisisindeedbeing
placedonthestabilityorinstabilityofatheroscleroticplaquesandthe
associated risk of rupture.
Inconclusion,whencomparedwithplacebo,infusionsofCER-001
did not result in a signiﬁcant reduction in coronary atherosclerosis
...............................................................................................................................................................................
Table5 Majoradversecardiovascularevents(positivelyadjudicated)occurringbetweentheﬁrstadministrationofstudy
drug and 6 months after the last dose of study drug in patients who received at least one infusion of study drug
Patients with at least one event Placebo
(n 5 120)
CER-001, 3 mg/kg
(n 5 120)
CER-001, 6 mg/kg
(n 5 124)
CER-001,12 mg/kg
(n 5 122)
Any MACE 10 (8.3%) 16 (13.3%) 17 (13.7%) 12 (9.8%)
P-value (log-rank) N/A 0.24 0.19 0.69
Death 0 0 0 0
Cardiac arrest 0 0 0 0
Non-fatal MI (%) 1 (0.8) 1 (0.8) 3 (2.4) 4 (3.3)
Non-fatal stroke (%) 0 (0) 1 (0.8) 1 (0.8) 0 (0)
Coronary revascularization (%) 8 (6.7) 13 (10.8) 12 (9.7) 8 (6.6)
Hospitalization for unstable angina (%) 5 (4.2) 4 (3.3) 2 (1.6) 2 (1.6)
Hospitalization for heart failure (%) 0 (0) 1 (0.8) 1 (0.8) 1 (0.8)
GiventhattheP-valuefortheprimaryendpointwasnotsigniﬁcant,allP-valuesinthistablerepresentnominalvalues.AllMACEswereadjudicatedbyaclinicalendpointadjudication
committee.
MACE, major adverse cardiovascular event; MI, myocardial infarction.
...............................................................................................................................................................................
Table 6 Selected adverse events in patients who received at least one infusion of study drug
Safety population Placebo(n 5 120) CER-001,3 mg/kg(n 5 120) CER-001,6 mg/kg(n 5 124) CER-001,12 mg/kg(n 5 122)
Any serious AE (%) 8 (6.7) 14 (11.7) 14 (11.3) 11 (9.0)
Any adverse event (%) 96 (80.0) 98 (81.7) 86 (69.4) 90 (73.8)
Infusion-type reaction(%) 0 (0) 0 (0) 3 (2.4) 3 (2.5)
Drug hypersensitivity (%) 2 (1.7) 1 (0.8) 3 (2.4) 6 (4.9)
Rash (%) 0 (0) 2 (1.7) 1 (0.8) 3 (2.5)
Dyspnoea (%) 3 (2.5) 3 (2.5) 6 (4.8) 7 (5.7)
Nausea (%) 8 (6.7) 11 (9.2) 4 (3.2) 2 (1.6)
Diarrhoea (%) 3 (2.5) 7 (5.8) 4 (3.2) 3 (2.5)
AE, adverse event.
J.-C. Tardif et al. 3284as assessed by IVUS and QCA. Whether or not the non-signiﬁcant
reduction in coronary atheroma burden in those treated with
CER-001 3 mg/kg reﬂects a beneﬁcial effect of this lower dose will
have to await further investigation.
Supplementary material
Supplementary material is available at European Heart Journal online.
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